CLS Holdings USA, Inc. Reports Financial and Operational Results for December 2020

CLS Holdings USA, Inc. (CLSH) today announced the financial and operational results for its Nevada wholly owned subsidiaries for the month of December 2020

CLS Holdings USA, Inc. (OTCQB:CLSH)

As an essential business, we felt it was our responsibility to keep cannabis accessible. We’re proud to have served the community clean products in a safe environment all month long.”

— Andrew Glashow

LAS VEGAS, NV, UNITED STATES, January 19, 2021 / — CLS Holdings USA, Inc. (OTCQB: CLSH) (CSE: CLSH), the ''Company'' or ''CLS'', a diversified cannabis company operating as Cannabis Life Sciences, today announced the financial and operational results for its Nevada wholly owned subsidiaries for the month of December 2020 with net revenues of $1.49M and Gross Margin of 48.3%. The Company achieved a record increase in year-over-year revenue at its branded wholesale division, while retail sales continued to maintain steady growth. Given present economic conditions in Nevada, both divisions also offered significant promotional pricing on wholesale and retail menus in an effort to effectively serve their communities with affordable products.

CLS Nevada December 2020 Financial and Operational Highlights

-December 2020 total net revenue increased by 50.2% over December 2019.
-Retail division, Oasis Cannabis Dispensary, achieved a 50.7% increase in the average ticket total, from $36.04 in December 2019 to $54.30 in December 2020. This contributed to a year-over-year monthly revenue increase of 28.6%.
-CLS wholesale division, City Trees, saw a year-over-year increase in monthly revenue of 174%, driven by increasing market penetration and strategic partnership opportunities.
-Oasis Cannabis offered significant promotional pricing on flower products in the month of December in a coordinated initiative to provide accessible products to an economically challenged population in Las Vegas.

CLS subsidiaries achieved a revenue increase of 50.2% in December 2020 compared to December 2019, and an 89.5% increase over December 2018. The Company experienced a 2% decline in gross margin year-over-year as a result of significant promotions on both its wholesale and retail offerings. At its retail division, Oasis Cannabis, a coordinated campaign to provide flower products at lower margins, dubbed ‘Flower to the People’, was initiated in an effort to ensure access to products for the economically challenged community of Las Vegas. Despite these challenges, this division experienced its highest New Year’s Eve sales total in company history, recording a single day net revenue of $60,485.

“Nevada took a bigger economic hit than nearly any other state in the country in 2020,” noted Company President and COO Andrew Glashow. “We found ourselves in a fortunate position at the end of the year that allowed us to provide significant discounts to medical patients and recreational consumers alike. As an essential business, we felt it was our responsibility to keep cannabis accessible. We’re proud to have served the community clean products in a safe environment all month long.”

At the Company’s manufacturing subsidiary, City Trees, research and development on a new range of distillate products was finalized in December 2020. The new range of products is anticipated to be available in early February 2021. This division also experienced a 174% increase in year-over-year revenue, achieving a significant sales milestone driven in part by the continued success of its collaboration concentrate product with State Flower, which initially sold out at Oasis Cannabis in one week. Further, the brand’s market penetration has continued to increase since its relaunch in September 2020, with products now available in nearly 80% of dispensaries across Nevada. As new products are introduced to its menu and brand awareness continues to increase, the Company anticipates significant growth of this division in 2021.

About CLS Holdings USA, Inc.

CLS Holdings USA, Inc. (CLSH) is a diversified cannabis company that acts as an integrated cannabis producer and retailer through its Oasis Cannabis subsidiaries in Nevada and plans to expand to other states. CLS stands for "Cannabis Life Sciences," in recognition of the Company's patented proprietary method of extracting various cannabinoids from the marijuana plant and converting them into products with a higher level of quality and consistency. The Company's business model includes licensing operations, processing operations, processing facilities, sale of products, brand creation and consulting services.
Twitter: @CLSHoldingsUSA

Oasis Cannabis has operated a cannabis dispensary in the Las Vegas market since dispensaries first opened in Nevada in 2015 and has been recognized as one of the top marijuana retailers in the state. Its location within walking distance to the Las Vegas Strip and Downtown Las Vegas in combination with its delivery service to residents allows it to efficiently serve both locals and tourists in the Las Vegas area. In February 2019, it was named "Best Dispensary for Pot Pros" by Desert Companion Magazine. In August 2017, the company commenced wholesale offerings of cannabis in Nevada with the launch of its City Trees brand of cannabis concentrates and cannabis-infused products.

Founded in 2017, City Trees is a Nevada-based cannabis cultivation, production and distribution company. Offering a wide variety of products with consistent results, City Trees products are available in numerous dispensaries throughout the state of Nevada.

Forward Looking Statements

This press release contains certain ''forward-looking information'' within the meaning of applicable Canadian securities legislation and ''forward-looking statements'' as that term is defined in the Private Securities Litigation Reform Act of 1995 (collectively, the ''forward-looking statements''). These statements relate to, among other things, the impact of the COVID-19 virus on our business, the results of our initiatives to retain our employees and strengthen our relationships with our customers and community during the pandemic, the effect of our initiatives to expand market share and achieve growth during and following the pandemic, results of operations and financial performance, anticipated future events, and the effectiveness of our business practices during the pandemic. The continued spread of COVID-19 could have, and in some cases already has had, an adverse impact on our business, operations and financial results, including through disruptions in our cultivation and processing activities, supply chains and sales channels, and retail dispensary operations as well as a deterioration of general economic conditions including a possible national or global recession. Due to the speed with which the COVID-19 situation is developing and the uncertainty of its magnitude, outcome and duration, it is not possible to estimate its impact on our business, operations or financial results; however, the impact could be material. In some cases, you can identify forward looking statements by terminology such as ''may,'' ''might,'' ''will,'' ''should,'' ''intends,'' ''expects,'' ''plans,'' ''goals,'' ''projects,'' ''anticipates,'' ''believes,'' ''estimates,'' ''predicts,'' ''potential,'' or ''continue'' or the negative of these terms or other comparable terminology. These forward-looking statements are only predictions, are uncertain and involve substantial known and unknown risks, uncertainties and other factors which may cause our actual results, levels of activity or performance to be materially different from any future results, levels of activity or performance expressed or implied by these forward-looking statements. We cannot guarantee future results, levels of activity or performance. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered together with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events. See CLS Holdings USA filings with the SEC and on its SEDAR profile at for additional details.

Contact Information:

Chairman and CEO
Jeff Binder

President and COO
Andrew Glashow


Investor Relations:

Source: CLS Holdings USA, Inc.

Andrew Glashow
CLS Holdings USA, Inc.
+1 888-438-9132
email us here
Visit us on social media:

Source: EIN Presswire

ID R&D Addresses Bias in Facial Liveness With Latest Release

ID R&D Logo

Improving speed and increasing accuracy for all types of users and across various devices is critical to successfully using face for identity verification and authentication.”

— Alexey Khitrov, President, ID R&D

NEW YORK, NY, UNITED STATES, January 19, 2021 / — ID R&D, the award-winning biometrics and liveness technology provider, announced that the latest release of its passive facial liveness, IDLive Face 1.18, features algorithms that reduce AI bias across demographic groups. Inclusive product development is a top priority for ID R&D and a major focus of this release is closing accuracy gaps between ages, genders, and ethnicities.

As IDLive Face continues to experience rapid adoption by customers and partners across a growing number of countries, tackling the issue of AI bias emerged as a leading initiative. Addressing this industry-wide challenge includes investing in unbiased data collection and classification. A new machine learning pipeline in IDLive Face 1.18 further enables this initiative with improved model training for higher accuracy.

The number of IDLive Face customers grew exponentially in 2020 and now the product conducts millions of passive liveness checks monthly, across 38 countries. This growth speaks directly to market demand for ID R&D’s next generation, single image passive liveness detection solution. The unique approach uses the same selfie image that is used for facial matching, which not only makes the process imperceptible to users, but also invisible to fraudsters.

As liveness detection becomes commonplace for identity verification, particularly in the financial sector, it is critical that products are built on inclusive data sets to prevent discrimination.

“IDLive Face is a breakthrough product in that it provides proven accuracy in even the most demanding, regulated financial environments with use cases such as onboarding,” said Alexey Khitrov, President at ID R&D. “However, unlike alternative liveness products we have had a relentless focus on enabling a zero-friction user experience. Improving speed and increasing accuracy, including both false accepts and false rejects, for all types of users and across various devices is critical to successfully using face for identity verification and authentication.”

IDLive Face is the only single image passive facial liveness detection product to achieve iBeta Level 2 Presentation Attack Detection compliance. Learn more about IDLive Face or contact us for a demo.

Kim Martin
+1 4079283320
email us here
Visit us on social media:

IDLive Face Passive Facial Liveness Detection Demo

Source: EIN Presswire

Telegenetics in 2021: What to Expect

what is telegenetics

Telegenetics 2021

USA, January 19, 2021 / — Telehealth

The last few years have been exciting and fast-moving ones in the field of telegenetics and telemedicine. We have seen more and more telegenetics platforms coming to the market and also the development of some exciting AI-based platforms for genetic analysis and diagnosis.

What can we expect from the field of telegenetics in 2021?

A push for greater accessibility

Telegenetics is increasingly well known amongst genetic counselors and geneticists, and at the same time amongst increasing numbers of family physicians. This means that the use of telegenetics platforms is usually initiated by a clinician or doctor.

However, what we are going to see in 2021 is a greater push for accessibility, which allows patients and their families to access telegenetics platforms and diagnostic tools directly. This means patients with concerns and or symptoms of a rare disease can initiate their own genetic analysis. Let’s take the example of the FDNA telehealth platform. This analysis tool allows patients to schedule an online meeting with a genetic expert and allows them to directly upload a photo for facial screening, which will then generate their genetic analysis report.

This, of course, does not mean that we will see the replacement of genetic counselors and geneticists. Their roles will be as important as ever before, if not more so. In fact, this increased accessibility will mean a greater ability to be able to better connect genetic counselors and geneticists with patients directly and remotely, in the process removing obstacles to appointments, and at the same time reducing wait times for consultations.

A drive for comprehensive care

This means that telegenetics will develop, not just to provide a quicker and more accurate diagnosis, but also to provide a more complete 360 view of patients and their care. Using advanced AI technologies to generate genetic reports is an important part of telegenetics moving into 2021, but equally important are platforms that also connect patients with the necessary genetic experts. This is crucial to reach a full and comprehensive diagnosis, while also receiving essential support and assistance with the long-term management of a rare disease.

A greater emphasis on results for the patient, in terms of a diagnosis, involves combining telegenetic technology with the genetic and medical experts who can help patients manage their rare condition most effectively. Solutions that support patients throughout the entirety of their rare disease diagnosis is the future of telegenetics as it strives to deliver better patient care.

FDNA Telehealth’s approach to telegenetics doesn't just involve advanced screening technology. It also includes a network of genetic counselors and geneticists who complement the telegenetics platform.

A clearer path to affordability

Telegenetics in 2021 is set to become much more affordable. This means making it accessible to as many people as possible, with costs coming down and greater coverage by insurance companies. It also means enabling patients more direct access to telegenetics solutions.

A demand for greater accuracy

Accuracy is the watchword for telegenetics for 2021. It won’t just be about faster analysis but will mean much more accurate diagnosis too. There is a real need in the rare disease field to reduce the number of patients misdiagnosed. Research into misdiagnosis and Ehlers Danos, for example, shows that up to 56% of patients with the condition experienced at least one misdiagnosis before receiving a correct one. The only way to do this is with more precise and advanced technology.

FDNA’s platform has already analyzed over 250,000 rare patients and started them on their journey to a much more accurate diagnosis.

This drive for greater accuracy should be at the center of telegenetics in 2021 and beyond.

A real reduction in diagnosis times

The aim of telegenetics in 2021 will definitely be to reduce diagnosis times. Most rare disease patients currently wait, on average, up to 5 years for a correct diagnosis. In the meantime, this means their condition is not managed properly.

When it comes to genetic syndromes, improving patient care means delivering faster diagnosis for patients who so desperately need to be connected to the genetic experts that can provide the answers and support they need.

Continued advancements in AI technologies

Telegenetics in 2021 will see the development and improvement of the technologies driving telegenetics, especially in the field of genetic analysis and diagnosis. From facial screening technology to more advanced online telehealth platforms connecting patients to genetic experts, 2021 is going to be another fast-moving year when it comes to telegenetics technologies.

Telegenetics developed out of a need to make key genetic services more accessible to the patients and families who need these services most. In 2021, we expect to see telegenetics services reaching more patients and bringing more people closer to an accurate diagnosis. This, in turn, will mean a reduction in diagnostic journey times and ensure rare disease patients get the right information, support, care, and treatment for their condition.

Ido Rabiner
FDNA Telehealth
+1 877-327-0735
email us here

Source: EIN Presswire


World's First LGBTQ+ Meditation Courses

World’s First LGBTQ+ Meditation Courses

LGBTQ+ Meditation Courses - crafted by the LGBTQ+ Community

LGBTQ+ Meditation Courses – crafted by the LGBTQ+ Community

FISU Meditation Academy

FISU Meditation Academy

We have crafted the world's first LGBTQ+ Meditation Course beginning on Sunday, 31st January 2021 at 2 PM GMT / 9 AM EST.


We have crafted the world's first LGBTQ+ Meditation Course beginning on Sunday, 31st January 2021 at 2 PM GMT / 9 AM EST.

This 12 week course is built on our LGBTQ+ community meditators' profound and life changing experiences. Some of them are now teachers on this project to help spread the profound and life-transforming benefits of meditation to the LGBTQ+ community.

A perfect lockdown antidote!

There are many single meditation lessons and videos around the web for the community. Still, none are dedicated to taking you in a personal journey of self-discovery and strengthening over 12 weeks led by an LGBTQ+ instructor.

Ten live instructor-led sessions are delivered through our innovative course player integrated with Zoom, plus 45 self-paced study lessons via videos, audios and eBooks. The self-paced study lessons follow the course's path and deliver content relevant to the learner's experiences at this time.

Online Course Details and schedule:

Here are some of the many course benefits (an expanded version is on the site here:
• Coming Out – Gain strength to make it a celebration of your identity
• Self Acceptance & Loving Yourself
• Calm, Relaxation & Peace of Mind – Stop Mind Chatter
• Improve Mental Health Well-Being especially through lockdown
• Overcoming Depression – Meditation is more effective than medication
• Dealing with and accepting those who are homophobic or transphobic and Bullying
• How to deal with negative people and their opinions
• Cultivate Compassion & Forgiveness
• Be who you want to be – Gender does not define you
• Greater Self-Esteem and Confidence
• Sharpen Concentration and accelerate Cognition
• Scene Influences – easier to steer away from "scene" influences
• How to avoid Addictions, Promiscuity, and Dependencies

All these subjects are covered within the course plus many others.

Testimonials from the LGBTQ+ Community are here: (scroll down to testimonial area).

Our Great Value Course Pricing:
The entire 12-week course cost is a reasonable GB £199/Euro €230/USD $260 – with concessions for unemployed.

Course Sessions take place on Sundays at 2 PM GMT / 9 AM EST

75 Minute Free Introductory Talks (obligatory to attend before enrolling) are regularly scheduled.

Languages: Future Courses will be taught in English, Spanish or Greek.

FISU Meditation is a non-profit organisation and registered educational charity that teaches the art of Meditation and Spiritual Unfoldment. UK Charity No:

FISU does not have any employees worldwide, and it's teachers dedicate their time to help others as meditation has changed their lives and they want to help others change theirs.

FISU Meditation is lead by Guru Rajesh Ananda.
For more details, please contact:

FISU Meditation HQ, Marlborough Road, London, E4 9AL
Phone: Guru Rajesh Ananda Mobile: +447793 562103
Academy Online:
Main Website:
Philosophy Life-Skills Website:
Twitter: @rajeshananda
Platform: FISU's global operations run on the platform, where it was the first meditation school to adopt the platform. The FISU Meditation Academy is integrated with Salesforce.

Rajesh Ananda
FISU Meditation
+44 7793 562103
email us here
Visit us on social media:

Source: EIN Presswire

iWave's New Game-Changing Multi-Lens Scoring Elevates Fundraising Customization To New Heights

iWave #1 Fundraising Solution For Nonprofits

iWave Fundraising Solutions For Nonprofits

iWave's Industry First Multi-Lens Scoring revolutionizes how nonprofits can view their donors from completely different perspectives for even more customization

CHARLOTTETOWNE, PRINCE EDWARD ISLAND, CANADA, January 19, 2021 / — iWave, the industry’s top-rated fundraising intelligence solution, announced today the availability of its newest feature, Multi-Lens Scoring. This revolutionary feature has never been seen before in the nonprofit industry and it furthers iWave’s leadership in the fundraising intelligence space. With it, nonprofits can easily and quickly view their donors from completely different perspectives to help them maximize fundraising goals.

Our industry-first fundraising feature elevates customization to new heights
Nonprofit organizations can fully customize their fundraising experience in iWave based on their unique donors, missions, and goals. To understand how valuable this new feature can be, it’s important to know how iWave scores prospects. iWave is the only solution that uses affinity scores to provide a holistic view of a donor. We believe a donor’s giving interest is crucial to knowing how they will give to you. iWave’s customizable scoring preferences for capacity, propensity and affinity provide the foundation for Multi-Lens Scoring. With this new feature, you can now customize your searches based on even more personal data for a complete, well-rounded donor search.

You can use Multi-Lens Scoring to:
● Find your TOP prospects who care about your mission
● Sort and cultivate donors into groups that help you reach your GOALS, faster
● Cut your research time by seeing MORE information in a comprehensive way
● Find donors in places you’ve NEVER looked before
● Be ahead of the curve and ready to ADAPT to any organization or campaign changes

Using affinity to your fullest advantage – a new perspective
As an example, a hospital may have a capital campaign to raise funds for an Arts Therapy Facility. Within iWave’s settings, the hospital is able to select Healthcare as the primary affinity (giving interest) to find donors that have donated to healthcare organizations in the past and have a high capacity and history of giving. Thanks to Multi-Lens Scoring, the customization doesn’t stop here.

Now the hospital can set up another lens by selecting Arts and Culture as the primary affinity. Under this view, they will uncover prospects that have a track record of donating to arts and culture causes or those who are an executive or a board member at an arts and culture organization.

Then they can segment top prospects into two lists based on their affinity and look at them side-by-side. The fundraising team can then engage with each group using tailored messaging that focuses on their giving interest in either healthcare or arts and culture.

“Multi-lens screening makes it possible to change the results of your data set depending on the precise propensity, affinity, and giving capacity your organization needs to support each team and each project. From annual fund to membership to major and principal giving, multi-lens screening pinpoints the prospects you should reach out to now. I cannot wait to work with our clients to help them take advantage of this powerful new feature,” said Erin Lynch Moran, Partner, The Solas Group.

Change the game with 5 unique lenses
Ultimately, this innovative new feature means even more customization for your fundraising efforts. With 5 lenses to try, fundraisers can compare and contrast results, put together multiple lists to work through, and broaden horizons to new potential projects and donor segments.

“We pride ourselves in providing innovations quickly that will have an impact on your organization even more rapidly. We knew our clients needed something to set them apart and fundraise more effectively. Sometimes, it’s about taking a step back and looking at things differently,” said Mary Cote, VP Product, iWave.

This new feature is part of iWave’s cloud-native platform that boasts a fresh modern design and intuitive layout. The platform is faster, more powerful, and more scalable than before, allowing new enhancements and functionality to be added quickly and easily.

“At iWave, we pride ourselves on being at the forefront of nonprofit fundraising innovation with an agile development process that leverages client and industry insights to continuously bring more value, along with the best customer service in the industry to our nonprofits, higher education, and healthcare organizations," said Ross Beattie, President & CEO, iWave. "We know we’re changing the game with this new
feature and we are excited to see how our clients can succeed and do more for their communities with our help.”

Check out our latest blog post on this exciting new feature here.

About iWave
iWave, the industry’s top-rated fundraising intelligence solution, enables nonprofit organizations to fundraise with confidence. In a new era of nonprofit fundraising, iWave solves critical challenges facing fundraising professionals today: how to identify, qualify and retain donors to raise more major gifts. iWave’s intuitive and easy-to-use solutions give access to the industry’s highest quality wealth and philanthropic information so you can determine who to ask, how much to ask for, and when to ask. Since 1991, over 6000 clients, including many of the largest education, healthcare and nonprofit organizations in the World, have relied on iWave to power their fundraising efforts. Visit our website and blog, follow us on Twitter and LinkedIn and like us on Facebook and Instagram.

Dana Prestigiacomo
+1 800-655-7729
email us here

Source: EIN Presswire

NovaQuest Private Equity Acquires CoreRx, Inc.

New Strategic Financial Sponsor to Support Continued Growth and Capability Expansion

CLEARWATER, FLORIDA, UNITED STATES, January 19, 2021 / — NovaQuest Private Equity Acquires CoreRx, Inc.
New Strategic Financial Sponsor to Support Continued Growth and Capability Expansion
For immediate release

NovaQuest Private Equity (“NovaQuest”) today announced its acquisition of CoreRx, Inc., a global contract development and manufacturing organization (“CDMO”).

Based in Clearwater, FL, CoreRx provides clinical and commercial CDMO services to a wide range of small to mid-sized pharmaceutical and biotech clients. Founded in 2006, the Company offers preformulation, formulation, analytical and stability, clinical manufacturing, commercial manufacturing, and packaging services. The Company’s deep development expertise allows it to solve complex formulation challenges. Its small-batch manufacturing capabilities, coupled with a responsive customer mindset, allow CoreRx to be a nimble, hands-on partner for its valued customers.

“This transaction is an endorsement of CoreRx’s success to date and its potential for future growth with NovaQuest, a firm with deep healthcare and life sciences expertise and a long history of partnering with market-leading businesses to take them to the next level,” said Todd R. Daviau, President and CEO of CoreRx. “NovaQuest’s expertise in pharmaceutical services and enabling technologies will be invaluable as we look to further grow and enhance the value of our business in partnership with our customers.”

“Todd and his management team have done an excellent job building CoreRx from the ground up, growing from a small development organization into a high-quality, end-to-end CDMO with proven commercial capabilities,” said Ashton Poole and Jeff Edwards, Partners at NovaQuest. “We look forward to supporting the CoreRx team as they continue to build out their capabilities and provide best-in-class service to the pharmaceutical industry.”
Affiliates of Signet Healthcare Partners will retain a minority position. Deal terms were not announced.

Goldman Sachs Specialty Lending Group provided debt financing for the transaction. William Blair & Company served as exclusive financial advisor to CoreRx. Sheppard Mullin and Johnson Pope served as legal advisors to CoreRx, and Smith Anderson served as legal advisor to NovaQuest.

About CoreRx:
CoreRx is a CDMO with full-service capabilities to support clinical through commercial manufacturing, offering state of the art facilities to support your supply chain needs. Our integrated offerings provide comprehensive services for the development, manufacturing, and testing of solid, liquid, and semi-solid dosage forms. For more information, please visit

About NovaQuest Private Equity:
NovaQuest Private Equity is a leading investor in technology and services companies in the life sciences and healthcare sectors. NovaQuest was formed in 2000 with the vision of building an investment platform to provide strategic capital and operational leverage in partnership with strong management teams. The investment team consists of highly seasoned operational and investment professionals with significant investment experience and deep life science and healthcare expertise. Furthermore, NovaQuest benefits from an extensive network of industry experts and relationships that assist in identifying, analyzing, and growing NovaQuest portfolio companies and investments. For more information, please visit


Mark DaFonseca
CoreRx, Inc.
email us here
Visit us on social media:

Source: EIN Presswire

North Carolina US Navy Veterans Lung Cancer Advocate Has Endorsed the Lawyers at Karst von Oiste to Assist a Navy Veteran with Lung Cancer-Who Also Had Asbestos Exposure-Compensation May Exceed $100,000

North Carolina

"If you are a Navy Veteran with lung cancer and you had exposure to asbestos in the navy please call the lawyers at the law firm of Karst von Oiste about what might be significant compensation. ”

— North Carolina US Navy Veterans Lung Cancer Advocate

CHARLOTTE , NORTH CAROLINA, USA, January 19, 2021 / — The North Carolina US Navy Veterans Lung Cancer Advocate says, "If you are a Navy Veteran with recently diagnosed lung cancer and you had heavy exposure to asbestos while serving in the navy please call the lawyers at the law firm of Karst von Oiste at 800-714-0303 about what might be significant financial compensation. In some to many instances-financial compensation for a person like this might exceed $100,000 and the claim does not involve suing the navy. The person we are trying to identify is over 60 years old and their asbestos exposure occurred on a navy ship, submarine or at a shipyard in the 1960s or 1970s. It does not matter if this person smoked cigarettes.

"If your husband or dad is a Navy Veteran has just been diagnosed with lung cancer and you know he had significant exposure to asbestos in the navy prior to 1982 please call the lawyers at the law firm of Karst von Oiste anytime at 800-714-0303 to discuss compensation. Most people like this do not realize the $30 billion dollar-asbestos trust funds were set up for them too. You have nothing to lose by calling the lawyers at Karst von Oiste if the person we have described is you or your loved one."

The North Carolina US Navy Veterans Lung Cancer Advocate’s free services are available to people with asbestos exposure lung cancer or mesothelioma in Charlotte, Raleigh, Greensboro, Winston-Salem, Fayetteville, Asheville, Wilmington or anywhere in North Carolina. https://NorthCarolina.USNavyLungCancer.Com

High-risk work groups for exposure to asbestos in North Carolina include Veterans of the US Navy, civilian workers at Fort Bragg, a worker at one of North Carolina’s dozens of power plants, steel mill workers, pulp, or paper mill workers, public utility workers, factory workers, plumbers, welders, insulators, millwrights, electricians, coal miners, auto mechanics, machinists, and construction workers. Typically, the exposure to asbestos occurred in the 1950’s, 1960’s, 1970’s, or 1980’s.

According to the American Cancer Society for nonsmokers who have been exposed to asbestos in their workplace the risk of lung cancer is five times that of unexposed workers.

The US Navy Veterans Lung Cancer Advocate says, “If your husband, dad, coworker or neighbor has just been diagnosed with lung cancer and you know they had significant exposure to asbestos in the navy, at a shipyard or while working at a factory, at power plant, public utility, or as a plumber, electrician welder, mechanic or any kind of skilled trades group in any state please have them call us anytime at 800-714-0303. Most people like this never get compensated-even though the asbestos trust funds were set up for them too. We are trying to change this sad fact.” https://USNavyLungCancer.Com

States with the highest incidence of lung cancer include Kentucky, West Virginia, Maine, Tennessee, Mississippi, Ohio, Indiana, Louisiana, Arkansas, Missouri, North Carolina, Rhode Island, Alabama, and Delaware.

For more information about asbestos exposure please visit the NIH’s website on this topic: substances/asbestos/asbestos-fact-sheet.

Michael Thomas
North Carolina US Navy Veterans Lung Cancer Advocate
+1 800-714-0303
email us here

Source: EIN Presswire

Masina Hospital with ReLiva Physiotherapy & Rehab Offers Comprehensive Post COVID Rehab

Recovery post Covid 19 with RespiRehab Pulmonary Rehab program by ReLiva Physiotherapy

Recovery post Covid 19 with RespiRehab Pulmonary Rehab program by ReLiva Physiotherapy

Recover from Covid symptoms like breathlessness, fatigue, cough and weakness with RespiRehab Pulmonary Rehab

Recover from Covid symptoms with RespiRehab Pulmonary Rehab

Personalised Pulmonary Rehab with Respiratory therapists from Reliva Physiotherapy

Personalised Pulmonary Rehab with Respiratory therapists from Reliva Physiotherapy

Masina Hospital offers affordable post COVID rehab with ReLiva Physiotherapy – Respirehab to improve breathing & lung function; ease body pain and fatigue.

At ReLiva, we believe that every patient deserves a complete recovery. We want to assist people to put COVID-19 behind and get their lives back.”

— Subodh Gupta, Founder and CEO of ReLiva Physiotherapy & Rehab

MUMBAI, MAHARASHTRA, INDIA, January 19, 2021 / — For many COVID-19 patients, the battle to breathe well continues well after the discharge from hospital. Many of the patients who develop moderate to severe symptoms of COVID-19 will require rehabilitation after they are discharged or risk developing chronic lung issues that can significantly impair their quality of life and ability to return to work.

Masina Hospital a leading private charitable trust hospital, now offers affordable and comprehensive post COVID rehabilitation in partnership with ReLiva Physiotherapy & Rehab (Respirehab Pulmonary Rehabilitation Program). The post COVID rehab program has been designed in accordance with evidence based international guidelines and is supervised by Cardiorespiratory physiotherapists. Respirehab focuses not only to improve breathing capacity and lung function, it also assists patients with other long covid symptoms such as musculoskeletal pain, fatigue and vertigo.

For patients who are unable to visit the clinic, Respirehab is also available through tele-physiotherapy at Respirehab has successfully assisted many patients in their fight with breathlessness and fatigue post COVID. A study published in Indian Journal of Physiotherapy & Occupational Therapy showed an average 71% improvement in respiratory function (measured by SGRQ) and almost 100% improvement in exercise capacity (measured by 1 RM-10RM) for patients after 1-month Respirehab program.

Speaking about Respirehab Pulmonary Rehabilitation Program, Dr Sonam Solanki, Consultant Pulmonologist, said: "A guided and supervised pulmonary rehabilitation makes a significant difference to well-being of the patients. It is important for patients to undergo the rehabilitation to ensure complete recovery."

Subodh Gupta, Founder and CEO of ReLiva Physiotherapy & Rehab says “At ReLiva, we believe that every patient deserves a complete recovery. We want to assist people to put COVID-19 behind and get their lives back.”

Know More about Post Covid Rehab with Respirehab at :

Watch a Patient Recovery feedback video: Covid Patient talks about post corona experience with Respirehab at

Here is another Patient Feedback for recovery with Respirehab :

About Respirehab Pulmonary Rehabilitation Program:
Respirehab is a comprehensive pulmonary rehab offering from ReLiva Physiotherapy & Rehab, India’s leading Physiotherapy organization. Post Covid Respirehab programme has been developed by cardio respiratory physiotherapists and is being delivered in person at Masina Hospital and also digitally for patients at home. For more information, please visit

About Masina Hospital:
Masina Hospital Trust is first and oldest healthcare setup in Mumbai with an illustrious history and goodwill spanning generations. The hospital is run with primary, secondary and tertiary care solutions with an emphasis on holistic service in a safe and clean environment, emphasizing on eco-friendly practices. The hospital works for all sections of the society without any bias or discrimination related to gender, community, caste or socio-economic status.

Vaishali Gupta
ReLiva Physiotherapy & Rehab
+91 99209 91584

Patient Recovery feedback with Post Covid Respirehab Pulmonary Rehabilitation Program from ReLiva Physiotherapy

Source: EIN Presswire

New Hampshire Mesothelioma Victims Center Appeals to the Family of a Navy Veteran with Mesothelioma in New Hampshire to Call Attorney Erik Karst of Karst von Oiste About Expedited Compensation

"Rather than ordering anything 'free' on the Internet when it comes to mesothelioma compensation-please call attorney Erik Karst of Karst von Oiste at 800-714-0303. Erik Karst is amazing.”

— New Hampshire Mesothelioma Victims Center

MANCHESTER , NEW HAMPSHIRE, USA, January 19, 2021 / — The New Hampshire Mesothelioma Victims Center is appealing to the wife or adult son-daughter of a Navy Veteran who has just been diagnosed with mesothelioma in New Hampshire to get serious about financial compensation and to call attorney Erik Karst of the law firm of Karst von Oiste about what could be significant financial compensation-that might exceed a million dollars. In some instances-Erik Karst and his amazing team at Karst von Oiste can expedite financial compensation. If a person with mesothelioma in New Hampshire is serious about compensation it is vital they hire a lawyer that knows what they are doing. For direct access to attorney Erik Karst of the law firm of Karst von Oiste please call 800-714-0303-anytime.

The group says, "We are warning a family of an individual with mesothelioma to steer clear of online 'freebies' offering kits, guides, booklets, calculators, five minute compensation tests-because all these 'free' things are intended to do is identify people with mesothelioma-and then the sponsor lawyers hound them night and day. Rather than ordering anything 'free' on the Internet when it comes to mesothelioma compensation-please call attorney Erik Karst of Karst von Oiste at 800-714-0303. He is an amazing resource, and he knows what he is talking about."

The New Hampshire Mesothelioma Victims Center’s free services are available to a person with mesothelioma anywhere in New Hampshire including communities such as Manchester, Nashua, Concord, Dover, Rochester, Keene, Derry, or Portsmouth.

For the best possible treatment options in New Hampshire we strongly recommend the following heath care facility with the offer to help a diagnosed victim, or their family get to the right physicians at this hospital. Norris Cotton Cancer Center:

High risk occupations for asbestos exposure in New Hampshire include the US Navy, shipyard workers, manufacturing workers, electricians, welders, plumbers, machinists, mechanics, power plant workers, paper mill workers, auto/truck brake technicians and construction workers.

For more information about mesothelioma please refer to the National Institutes of Health’s web site related to this rare form of cancer:

Michael Thomas
New Hampshire Mesothelioma Victims Center
+1 800-714-0303
email us here

Source: EIN Presswire

Social Assistance Market Employs Big Data Analytics To Gather Insights For Social Services

Social Assistance Market Report 2021: COVID-19 Impact And Recovery To 2030

Social Assistance Global Market Report 2021: COVID-19 Impact And Recovery To 2030

The Business Research Company’s Social Assistance Global Market Report 2021: COVID-19 Impact and Recovery to 2030

LONDON, GREATER LONDON, UK, January 19, 2021 / — New year, new updates! Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact:

Social assistance providers are increasingly using data-driven approaches such as big data and predictive analytics to gather insights related to social assistance services. Predictive analytics involves the use of data, statistical algorithms and machine learning techniques to identify the likelihood of future outcomes based on historical data. Big data analytics involves extracting hidden patterns and useful information from a large set of data. These techniques help in reporting, detecting, or correcting a non-compliance while monitoring target population. In the social services industry overview for example, Hillside Family of Agencies, a human services provider for youth and families, is using predictive analytics to reduce the dropout rates among youth in high school. Good Samaritan Society, a non-profit provider of senior care and services, has partnered with IBM to use big data and analytics software for its clinical and operational data about the patients.

The global social assistance market is expected to grow from $1.28 trillion in 2020 to $1.43 trillion in 2021 at a compound annual growth rate (CAGR) of 11.3%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. As per social assistance industry analysis, the healthcare and social assistance market is expected to reach $1.95 trillion in 2025 at a CAGR of 8%.

Here Is A List Of Similar Reports By The Business Research Company:

Social Services Global Market Report 2021: COVID-19 Impact and Recovery to 2030

Community And Individual Services Global Market Report 2021: COVID-19 Impact and Recovery to 2030

Interested to know more about The Business Research Company?
The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
Visit us on social media:

Source: EIN Presswire